Comparative Pharmacology
Head-to-head clinical analysis: ABILIFY ASIMTUFII versus ABILIFY MAINTENA KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ABILIFY ASIMTUFII versus ABILIFY MAINTENA KIT.
ABILIFY ASIMTUFII vs ABILIFY MAINTENA KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aripiprazole is a partial agonist at D2 and 5-HT1A receptors and an antagonist at 5-HT2A receptors. The active metabolite, dehydro-aripiprazole, contributes to the pharmacological activity. Abilify Asimtufii is a long-acting injectable formulation for intramuscular use.
Aripiprazole is a partial agonist at D2 and 5-HT1A receptors and an antagonist at 5-HT2A receptors, stabilizing dopamine and serotonin activity.
Recommended starting dose: 400 mg intramuscularly once monthly, with a single oral dose of 10-20 mg aripiprazole or continued oral therapy for 14 days to ensure tolerability. Maintenance dose: 300-400 mg monthly.
400 mg IM once monthly after establishing tolerability with oral aripiprazole.
None Documented
None Documented
Terminal elimination half-life: 29-40 days (aripiprazole) and 48-63 days (dehydraripiprazole), allowing monthly dosing.
Aripiprazole: 75-146 hours; dehydro-aripiprazole: 94-146 hours. Long half-life allows monthly intramuscular dosing.
Renal (approximately 25% unchanged and 55% as metabolites), fecal (approximately 20%).
Renal (approximately 25% unchanged and 55% as metabolites); fecal (approximately 20% as metabolites).
Category C
Category C
Atypical antipsychotic
Atypical antipsychotic